scholarly journals Expression of CD146 and Regenerative Cytokines by Human Placenta-Derived Mesenchymal Stromal Cells upon Expansion in Different GMP-Compliant Media

2021 ◽  
Vol 2021 ◽  
pp. 1-10
Author(s):  
Frederik Peissert ◽  
Hannah D. E. Graf ◽  
Bettina Müller ◽  
Tanja Abruzzese ◽  
Harald Abele ◽  
...  
Keyword(s):  
Human Serum ◽  
Mesenchymal Stromal Cells ◽  
Stromal Cells ◽  
Feasibility Studies ◽  
Accelerated Expansion ◽  
Human Term Placenta ◽  
Emergency Situations ◽  
Regenerative Cells ◽  
Expansion Media ◽  
Cd146 Expression

Mesenchymal stromal cells (MSCs) have been successfully employed in clinical applications. In most studies, autologous MSCs from the bone marrow (bmMSCs) were used, and others employed autologous adipose tissue-derived stromal cells (ADSCs). Recently, clinical feasibility studies provided evidence that MSCs from human term placenta (pMSCs) can be used for homologous therapy facilitating access to regenerative cells in emergency situations, when autologous cells are not available or not suitable. We therefore investigated the expression of MSC stemness marker CD146 and the expression of neuro- and myoregenerative cytokines by human pMSCs after expansion in three different media compliant with good manufacturing protocols (GMP) in comparison to pMSCs expanded in a commercial MSC expansion media. To replace xenobiotic serum in the GMP-compliant media employed in this study, either human serum, human serum plus platelet lysate (PLL), or human plasma plus PLL was used. We report that enrichment of media with PLL accelerates pMSC proliferation but reduces the expression of the stemness marker CD146 significantly, while PLL deprivation enhanced the CD146 expression. In contrast, the reduced expression of CD146 by PLL deprivation was not observed on bmMSCs. The expression of the cytokines investigated was not modulated significantly by PLL. We conclude that accelerated expansion of pMSCs in GMP-compliant media enriched by PLL reduces the expression of stemness marker CD146, but does not influence the expression of neuro- and myoregenerative cytokines.

scholarly journals Propagation of pure fetal and maternal mesenchymal stromal cells from terminal chorionic villi of human term placenta

2015 ◽  
Vol 5 (1) ◽  
Author(s):  
Smitha Mathews ◽  
K. Lakshmi Rao ◽  
K. Suma Prasad ◽  
M. K. Kanakavalli ◽  
A. Govardhana Reddy ◽  
...  
Keyword(s):  
Mesenchymal Stromal Cells ◽  
Stromal Cells ◽  
Human Term Placenta ◽  
Chorionic Villi ◽  
Term Placenta

scholarly journals The Impact of Various Culture Conditions on Human Mesenchymal Stromal Cells Metabolism

2021 ◽  
Vol 2021 ◽  
pp. 1-15
Author(s):  
Pavla Tonarova ◽  
Katerina Lochovska ◽  
Robert Pytlik ◽  
Marie Hubalek Kalbacova
Keyword(s):  
Human Serum ◽  
Mesenchymal Stromal Cells ◽  
Stromal Cells ◽  
Reciprocal Relationship ◽  
Heat Inactivation ◽  
High Quality ◽  
Native Form ◽  
The Impact

In vitro and in vivo analyses are closely connected, and the reciprocal relationship between the two comprises a key assumption with concern to the conducting of meaningful research. The primary purpose of in vitro analysis is to provide a solid background for in vivo and clinical study purposes. The fields of cell therapy, tissue engineering, and regenerative medicine depend upon the high quality and appropriate degree of the expansion of mesenchymal stromal cells (MSCs) under low-risk and well-defined conditions. Hence, it is necessary to determine suitable alternatives to fetal bovine serum (FBS—the laboratory gold standard) that comply with all the relevant clinical requirements and that provide the appropriate quantity of high-quality cells while preserving the required properties. Human serum (autologous and allogeneic) and blood platelet lysates and releasates are currently considered to offer promising and relatively well-accessible MSC cultivation alternatives. Our study compared the effect of heat-inactivated FBS on MSC metabolism as compared to its native form (both are used as the standard in laboratory practice) and to potential alternatives with concern to clinical application—human serum (allogeneic and autologous) or platelet releasate (PR-SRGF). The influence of the origin of the serum (fetal versus adult) was also determined. The results revealed the key impact of the heat inactivation of FBS on MSCs and the effectiveness of human sera and platelet releasates with respect to MSC behaviour (metabolic activity, proliferation, morphology, and cytokine production).

scholarly journals The Analysis of In Vivo Aging in Human Bone Marrow Mesenchymal Stromal Cells Using Colony-Forming Unit-Fibroblast Assay and the CD45lowCD271+ Phenotype

2019 ◽  
Vol 2019 ◽  
pp. 1-14 ◽  
Author(s):  
Payal Ganguly ◽  
Jehan J. El-Jawhari ◽  
Agata N. Burska ◽  
Frederique Ponchel ◽  
Peter V. Giannoudis ◽  
...  
Keyword(s):  
Gene Expression ◽  
Bone Marrow ◽  
Flow Cytometry ◽  
Human Serum ◽  
Mesenchymal Stromal Cells ◽  
Stromal Cells ◽  
Connexin 43 ◽  
Colony Forming Unit ◽  
Age Related ◽  
Old Donor

Uncultured mesenchymal stromal cells (MSCs) are increasingly used in therapies; however, the effects of donor age on their biological characteristics and gene expression remain unclear. The aim of this study was to investigate age-related changes in bone marrow (BM) MSCs following minimal or no culture manipulation. Iliac crest BM was aspirated from 67 healthy donors (19-89 years old) and directly used for the colony-forming unit-fibroblast (CFU-F) assay or CD45lowCD271+ cell enumeration. The colonies were analysed for colony area and integrated density (ID) when grown in standard MSC media or media supplemented with human serum from young (YS) or old (OS) donors. There was a notable age-related decline in the number of MSCs per millilitre of BM aspirate revealed by the CFU-F assay (r=−0.527, p<0.0001) or flow cytometry (r=−0.307, p=0.0116). Compared to young donors (19-40 years old), colony IDs were significantly lower in older donors (61-89 years old), particularly for smaller-sized colonies (42% lower, p<0.01). When cultured in media supplemented with OS, young and old donor MSCs formed colonies with lower IDs, by 21%, p<0.0001, and 27%, p<0.05, respectively, indicating the formation of smaller sparser colonies. No significant differences in the expression of selected adipogenic, osteogenic, stromal, and bone remodelling genes as well as CD295, CD146, CD106, and connexin 43 surface molecules were found in sorted CD45lowCD271+ MSCs from young and old donors (n=8 donors each). Altogether, these results show similar trends for age-related decline in BM MSC numbers measured by the CFU-F assay and flow cytometry and reveal age-related effects of human serum on MSC colony formation. No significant differences in selected gene expression in uncultured CD45lowCD271+ MSCs suggest that old donor MSCs may not be inferior in regard to their multipotential functions. Due to large donor-to-donor variation in all donor groups, our data indicate that an individual’s chronological age is not a reliable predictor of their MSC number or potency.

scholarly journals Allogenic Use of Human Placenta-Derived Stromal Cells as a Highly Active Subtype of Mesenchymal Stromal Cells for Cell-Based Therapies

2021 ◽  
Vol 22 (10) ◽  
pp. 5302
Author(s):  
Raphael Gorodetsky ◽  
Wilhelm K. Aicher
Keyword(s):  
Mesenchymal Stromal Cells ◽  
Human Placenta ◽  
Stromal Cells ◽  
Therapeutic Potential ◽  
Feasibility Studies ◽  
Hla Class I ◽  
Inflammatory Factors ◽  
Competent Cell ◽  
Wide Range ◽  
Anti Inflammatory

The application of mesenchymal stromal cells (MSCs) from different sources, including bone marrow (BM, bmMSCs), adipose tissue (atMSCs), and human term placenta (hPSCs) has been proposed for various clinical purposes. Accumulated evidence suggests that the activity of the different MSCs is indirect and associated with paracrine release of pro-regenerative and anti-inflammatory factors. A major limitation of bmMSCs-based treatment for autologous application is the limited yield of cells harvested from BM and the invasiveness of the procedure. Similar effects of autologous and allogeneic MSCs isolated from various other tissues were reported. The easily available fresh human placenta seems to represent a preferred source for harvesting abundant numbers of human hPSCs for allogenic use. Cells derived from the neonate tissues of the placenta (f-hPSC) can undergo extended expansion with a low risk of senescence. The low expression of HLA class I and II on f-hPSCs reduces the risk of rejection in allogeneic or xenogeneic applications in normal immunocompetent hosts. The main advantage of hPSCs-based therapies seems to lie in the secretion of a wide range of pro-regenerative and anti-inflammatory factors. This renders hPSCs as a very competent cell for therapy in humans or animal models. This review summarizes the therapeutic potential of allogeneic applications of f-hPSCs, with reference to their indirect pro-regenerative and anti-inflammatory effects and discusses clinical feasibility studies.

Regeneration of mandibular defects using adipose tissue mesenchymal stromal cells in combination with human serum-derived scaffolds

2016 ◽  
Vol 44 (9) ◽  
pp. 1356-1365 ◽  
Author(s):  
Ignacio Peña González ◽  
María Álvarez-Viejo ◽  
Cristina Alonso-Montes ◽  
Yolanda Menéndez-Menéndez ◽  
Fernando Gutiérrez Álvarez ◽  
...  
Keyword(s):  
Adipose Tissue ◽  
Human Serum ◽  
Mesenchymal Stromal Cells ◽  
Stromal Cells

scholarly journals Mesenchymal Stromal Cells Cultured in Serum from Heart Failure Patients Are More Resistant to Simulated Chronic and Acute Stress

2018 ◽  
Vol 2018 ◽  
pp. 1-15
Author(s):  
Timo Z. Nazari-Shafti ◽  
Zhiyi Xu ◽  
Andreas Matthäus Bader ◽  
Georg Henke ◽  
Kristin Klose ◽  
...  
Keyword(s):  
Heart Failure ◽  
Human Serum ◽  
Cell Survival ◽  
Mesenchymal Stromal Cells ◽  
Stromal Cells ◽  
Acute Stress ◽  
Autologous Serum ◽  
Heart Failure Patients ◽  
Acute And Chronic Stress ◽  
Healthy Donors

Despite regulatory issues surrounding the use of animal-derived cell culture supplements, most clinical cardiac cell therapy trials using mesenchymal stromal cells (MSCs) still rely on fetal bovine serum (FBS) for cell expansion before transplantation. We sought to investigate the effect of human serum from heart failure patients (HFS) on cord blood MSCs (CB-MSCs) during short-term culture under regular conditions and during simulated acute and chronic stress. Cell survival, proliferation, metabolic activity, and apoptosis were quantified, and gene expression profiles of selected apoptosis and cell cycle regulators were determined. Compared to FBS, HFS and serum from healthy donors (CS) showed similar effects by substantially increasing cell survival during chronic and acute stress and by increasing cell yields 5 days after acute stress. Shortly after the termination of acute stress, both HFS and CS resulted in a marked decrease in apoptotic cells. Transcriptome analysis suggested a decrease in TNF-mediated induction of caspases and decreased activation of mitochondrial apoptosis. Our data confirm that human serum from both healthy donors and heart failure patients results in increased cell yields and increased resistance to cellular stress signals. Therefore, we consider autologous serum a valid alternative to FBS in cell-based therapies addressing severe heart disease.

Human Term Placenta-Derived Mesenchymal Stromal Cells Are Less Prone to Osteogenic Differentiation Than Bone Marrow-Derived Mesenchymal Stromal Cells

2011 ◽  
Vol 20 (4) ◽  
pp. 635-646 ◽  
Author(s):  
Gregor A. Pilz ◽  
Christine Ulrich ◽  
Manuel Ruh ◽  
Harald Abele ◽  
Richard Schäfer ◽  
...  
Keyword(s):  
Bone Marrow ◽  
Osteogenic Differentiation ◽  
Mesenchymal Stromal Cells ◽  
Stromal Cells ◽  
Human Term Placenta ◽  
Term Placenta
Sign in / Sign up

Export Citation Format

Share Document